Iovance Revenue Rises 80% on Amtagvi Demand

Iovance Biotherapeutics reported record third-quarter 2026 revenue and a narrower net loss versus the year-earlier period.

Updated on Nov. 6, 2026 in Biotech

Stainless-steel bioreactor vessels stand in a clean, empty laboratory bay beneath soft daylight from large windows. — Iovance Biotherapeutics reported third-quarter 2026 revenue of $121.5 million, up 80% year over year, as U.S. demand for its melanoma therapy Amtagvi grew. AI Illustration. Upload story photo >

Iovance Biotherapeutics reported 80% year-over-year revenue growth for the quarter ended September 30, 2026, with total revenue of $121.469 million. The company's net loss narrowed to $22.271 million from $91.253 million in the third quarter of 2025.

Why it matters

The quarter's growth was driven by continued U.S. demand for Amtagvi, a treatment for previously treated advanced melanoma. The company also reported its highest gross margin to date, signaling improving economics for its tumor-infiltrating lymphocyte therapies.

The figures come from Iovance's third-quarter 2026 financial results, showing $121.469 million in revenue versus $67.455 million a year earlier. U.S. Amtagvi accounted for about $102 million of the quarter's revenue, up 77% year over year, while the company held roughly $382 million in cash as of September 30, 2026.

The players

Iovance Biotherapeutics

Iovance Biotherapeutics is a clinical-stage biotechnology company developing tumor-infiltrating lymphocyte therapies for cancer, led by its Amtagvi melanoma treatment.

The details

Iovance, which focuses on tumor-infiltrating lymphocyte therapies, reported third-quarter revenue of about $122 million, a record for the company. Global Proleukin revenue contributed about $20 million in the quarter.

September 30, 2026: Quarter end and date of the reported $382 million cash position.
Third quarter 2026: Record revenue of about $122 million reported.
2026: Company expects total product revenue of $410 million to $420 million.

Under the Hood

Amtagvi, Iovance's tumor-infiltrating lymphocyte therapy for previously treated advanced melanoma, continues to anchor the company's commercial growth as U.S. revenue rose 77% year over year. The quarter's results mark another step in the product's ramp following its approval for advanced melanoma.

For patients with previously treated advanced melanoma, the growth in Amtagvi demand reflects expanding availability of this therapy. The company's guidance for $410 million to $420 million in 2026 product revenue indicates continued commercial rollout.

The takeaway

Iovance's combination of 80% revenue growth and a narrowing loss shows the Amtagvi launch gaining commercial traction. Investors and patients alike can track whether the company meets its 2026 revenue target.